Non-small Cell Lung Cancer
📧 Sign up to get email alerts when something new happens for Non-small Cell Lung Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: FDG PET/CT in Lung Cancer Staging [NA]
This ClinicalTrials.gov entry reports the completed status of a study evaluating FDG PET/CT for staging non-small cell lung cancer.
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: 18F-PD-L1 PET/CT in Nivolumab Treated Patients With NSCLC [NA]
A completed clinical trial investigates 18F-PD-L1 PET/CT imaging in nivolumab-treated non-small cell lung cancer patients (Stage IV).
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: Treatment and Biomarker Testing Patterns,Treatment Outcomes in a/m NSCLC With and Without Actionable Genomic Alterations
An AstraZeneca-sponsored clinical trial update evaluating treatment and biomarker testing patterns and treatment outcomes in non-small cell …
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases [Phase 3]
A Phase 3 clinical trial comparing entrectinib with crizotinib in patients with advanced or metastatic ROS1-positive non-small cell lung can…
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. [Phase 2, Phase 3]
The DETERMINE trial's Arm 07 is studying dabrafenib plus trametinib in patients with BRAF V600 mutation-positive cancers across age groups; …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-02-25Clinical Trial Update: PRO1107 in Patients With Advanced Solid Tumors [Phase 1, Phase 2]
The Phase 1/2 PRO1107 trial in advanced solid tumors, including endometrial and ovarian cancers, has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation [Phase 2]
Phase 2 trial evaluating bevacizumab combined with double doses of icotinib in advanced non-small cell lung cancer with EGFR L858R mutation …
-
CLINICAL_TRIALS trial_result · 2026-02-24Clinical Trial Update: Understanding the Post-Surgical Non-Small Cell Lung Cancer Patient's Symptom Experience [NA]
A completed clinical trial update reports results related to symptoms and self-efficacy in post-surgical non-small cell lung cancer patients…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 3]
A Phase 3 study comparing cemiplimab (REGN2810) to platinum-based chemotherapy in metastatic non-small cell lung cancer has completed.
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [Phase 2, Phase 3]
This Phase 2/Phase 3 trial compares Livmoniplimab plus Budigalimab with chemotherapy versus Pembrolizumab plus chemotherapy as first-line tr…
-
CLINICAL_TRIALS trial_result · 2026-02-23Clinical Trial Update: A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines. [Phase 1]
Phase 1 study of PF-07826390 in cancer patients, including non-small cell lung cancer, was terminated; the trial evaluated different doses o…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Sarcopenia and CRP-TyG Index (CTI) as Predictors of Immunotherapy Response in Metastatic Non-Small Cell Lung Cancer
This completed clinical trial investigated whether sarcopenia and the CRP-TyG (CTI) index can predict response to immunotherapy in metastati…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer [Phase 2]
Phase 2 trial evaluating nivolumab with induction chemotherapy in resectable non-small cell lung cancer was terminated, and results have bee…
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC [Phase 2]
Phase 2 trial of poziotinib for EGFR exon 20-mutant or ERBB2-mutant advanced non-small cell lung cancer was terminated.
-
CLINICAL_TRIALS trial_result · 2026-02-20Clinical Trial Update: First in Human Study of AZD9592 in Solid Tumors [Phase 1]
First-in-human Phase 1 study of AstraZeneca’s AZD9592 in solid tumors is recruiting to evaluate safety, tolerability, and preliminary dosing…
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors [Phase 1]
A Phase 1 trial assessing IMP321 (eftilagimod alpha) for advanced solid tumors reports feasibility and safety findings.
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway [Phase 1]
A Phase 1 study evaluating MRTX0902 in solid tumors with KRAS MAPK pathway mutations has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-02-19Clinical Trial Update: PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors [Phase 1]
Phase 1 clinical trial update for PF-07265028 as a single agent and in combination with sasanlimab in advanced/metastatic solid tumors has b…
-
CLINICAL_TRIALS trial_result · 2026-02-18Clinical Trial Update: A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations [Phase 3]
A Phase 3 study of poziotinib in previously treated locally advanced or metastatic non-small cell lung cancer with HER2 exon 20 mutations ha…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer [Phase 1, Phase 2]
This clinical trial update reports a completed Phase 1/2 study of ALT-803 in combination with nivolumab for pretreatment, advanced or metast…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) [Phase 3]
A Phase 3 trial comparing DZD9008 with platinum-based doublet chemotherapy in locally advanced or metastatic non-small cell lung cancer; the…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors [Phase 1]
Phase 1 study of intravenous QEQ278 in patients with advanced solid tumors has been terminated.
-
CLINICAL_TRIALS trial_result · 2026-02-13Clinical Trial Update: A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors [Phase 1]
Phase I trial comparing HLX17 to Keytruda in multiple solid tumors to evaluate pharmacokinetics, preliminary efficacy, safety, and immunogen…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer [Phase 1, Phase 2]
A Phase 1/2 trial of Rucaparib plus Pembrolizumab as maintenance therapy in Stage IV non-squamous non-small cell lung cancer was terminated,…
-
CLINICAL_TRIALS trial_result · 2026-02-12Clinical Trial Update: Study of Palbociclib in Combination With Binimetinib for Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer [Phase 1]
A Phase 1 trial studied the combination of palbociclib and binimetinib in patients with advanced KRAS-mutant non-small cell lung cancer; the…